87 related articles for article (PubMed ID: 28974530)
1. Targeting the Noncoding Genome: Superenhancers Meet Their Kryptonite.
Wang E; Aifantis I
Cancer Discov; 2017 Oct; 7(10):1065-1066. PubMed ID: 28974530
[TBL] [Abstract][Full Text] [Related]
2. Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.
McKeown MR; Corces MR; Eaton ML; Fiore C; Lee E; Lopez JT; Chen MW; Smith D; Chan SM; Koenig JL; Austgen K; Guenther MG; Orlando DA; Lovén J; Fritz CC; Majeti R
Cancer Discov; 2017 Oct; 7(10):1136-1153. PubMed ID: 28729405
[TBL] [Abstract][Full Text] [Related]
3. Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.
Perez MW; Sias-Garcia O; Daramola A; Wei H; Terrell M; Rashid R; Park WD; Duong K; Horton TM; Li F; Cherayil N; Koren JV; Gant VU; Junco JJ; Curry CV; Stevens AM; Lin CY; Yi JS
Blood Adv; 2021 Dec; 5(23):4864-4876. PubMed ID: 34543389
[TBL] [Abstract][Full Text] [Related]
4. Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells.
Schimmer AD
Cancer Discov; 2017 Jul; 7(7):670-672. PubMed ID: 28684410
[TBL] [Abstract][Full Text] [Related]
5. BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
Pullarkat VA; Newman EM
Cancer Discov; 2016 Oct; 6(10):1082-1083. PubMed ID: 27698099
[TBL] [Abstract][Full Text] [Related]
6. Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA.
Keeshan K; Vieugué P; Chaudhury S; Rishi L; Gaillard C; Liang L; Garcia E; Nakamura T; Omidvar N; Kogan SC
Haematologica; 2016 Oct; 101(10):1228-1236. PubMed ID: 27390356
[TBL] [Abstract][Full Text] [Related]
7. Immunologic Targets in AML.
Ritz J
Blood Cancer Discov; 2023 Nov; 4(6):430-432. PubMed ID: 37847743
[TBL] [Abstract][Full Text] [Related]
8. Activating p53 and Inhibiting Superenhancers to Cure Leukemia.
Ball B; Abdel-Wahab O
Trends Pharmacol Sci; 2018 Dec; 39(12):1002-1004. PubMed ID: 30454768
[TBL] [Abstract][Full Text] [Related]
9. Eya2, a Target Activated by Plzf, Is Critical for
Ono R; Masuya M; Ishii S; Katayama N; Nosaka T
Mol Cell Biol; 2017 Jul; 37(13):. PubMed ID: 28416638
[TBL] [Abstract][Full Text] [Related]
10. Multiplex fusion gene testing in pediatric acute myeloid leukemia.
Iijima-Yamashita Y; Matsuo H; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Takahashi H; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
Pediatr Int; 2018 Jan; 60(1):47-51. PubMed ID: 29105243
[TBL] [Abstract][Full Text] [Related]
11. Novel analogs of 1,25-dihydroxyvitamin D
Nachliely M; Sharony E; Kutner A; Danilenko M
J Steroid Biochem Mol Biol; 2016 Nov; 164():59-65. PubMed ID: 26365556
[TBL] [Abstract][Full Text] [Related]
12. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets.
Su R; Lin HS; Zhang XH; Yin XL; Ning HM; Liu B; Zhai PF; Gong JN; Shen C; Song L; Chen J; Wang F; Zhao HL; Ma YN; Yu J; Zhang JW
Oncogene; 2015 Jun; 34(25):3226-39. PubMed ID: 25174404
[TBL] [Abstract][Full Text] [Related]
13. Characterization of purine-rich element binding protein B as a novel biomarker in acute myelogenous leukemia prognostication.
Kelm RJ; Lamba GS; Levis JE; Holmes CE
J Cell Biochem; 2018 Feb; 119(2):2073-2083. PubMed ID: 28834593
[TBL] [Abstract][Full Text] [Related]
14. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
15. CREB engages C/EBPδ to initiate leukemogenesis.
Tregnago C; Manara E; Zampini M; Bisio V; Borga C; Bresolin S; Aveic S; Germano G; Basso G; Pigazzi M
Leukemia; 2016 Sep; 30(9):1887-96. PubMed ID: 27118402
[TBL] [Abstract][Full Text] [Related]
16. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
Li C; Chen X; Yu X; Zhu Y; Ma C; Xia R; Ma J; Gu C; Ye L; Wu D
Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771
[TBL] [Abstract][Full Text] [Related]
17. AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.
Singh AA; Mandoli A; Prange KH; Laakso M; Martens JH
Oncotarget; 2017 Feb; 8(8):12855-12865. PubMed ID: 28030795
[TBL] [Abstract][Full Text] [Related]
18. Angiocidin induces differentiation of acute myeloid leukemia cells.
Tuszynski GP; Rothman VL
Exp Mol Pathol; 2013 Dec; 95(3):249-54. PubMed ID: 24036285
[TBL] [Abstract][Full Text] [Related]
19. Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells.
Daniele G; Simonetti G; Fusilli C; Iacobucci I; Lonoce A; Palazzo A; Lomiento M; Mammoli F; Marsano RM; Marasco E; Mantovani V; Quentmeier H; Drexler HG; Ding J; Palumbo O; Carella M; Nadarajah N; Perricone M; Ottaviani E; Baldazzi C; Testoni N; Papayannidis C; Ferrari S; Mazza T; Martinelli G; Storlazzi CT
Haematologica; 2017 Jul; 102(7):1204-1214. PubMed ID: 28411256
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia.
Chim CS; Wong SY; Pang A; Chu P; Lau JS; Wong KF; Kwong YL
Leukemia; 2005 Dec; 19(12):2241-6. PubMed ID: 16239915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
